Pemvidutide (ALT-801)
GLP-1/glucagon dual agonist with balanced 1:1 receptor ratio — distinct from survodutide. Primary clinical target is MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH). IMPACT Phase 2b (*Lancet* Nov 2025): MASH resolution without worsening fibrosis in up to 59.1% at 24 weeks.
This compound sits in research-grey territory. The caveats below carry more weight than for FDA-approved entries — read them.
Altimmune small biotech. The balanced 1:1 GLP-1:GCGR ratio (vs survodutide's glucagon-weighted ratio) is designed to maximize liver fat mobilization without the weight-loss primary endpoint driving the dosing schedule. IMPACT Phase 2b (212 participants, biopsy-confirmed F2/F3 fibrosis, 24 weeks, *Lancet* Nov 2025): MASH resolution without worsening fibrosis in up to 59.1%; fibrosis improvement without worsening MASH in up to 34.5%; 48-week ELF + Liver Stiffness Measurement statistically significant vs placebo. Weight loss was only 6.2% — lower than other GLP-1s because MASH-specific dosing prioritizes liver outcomes over weight. RECLAIM Phase 2 in alcohol use disorder (AUD) still enrolling. Phase 3 program planned 2026.
Different audience than weight-loss-primary GLP-1 users: pemvidutide is for the MASH/MAFLD/fatty-liver cohort — its 6.2% weight loss is modest compared to other entries in this cluster, but that's intentional (liver outcomes drive the dosing). Altimmune is a small biotech — different funding pressure profile than Big Pharma; Phase 2b biopsy-confirmed endpoints in the *Lancet* are credible but the effect size needs Phase 3 confirmation. AUD signal (RECLAIM Phase 2) is very preliminary — grade D.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Not FDA-approved. Phase 2b complete (IMPACT, *Lancet* 2025). Phase 3 program planned 2026. No NDA filed. No 503A compounding path.
Pre-filled with this compound's published dose range: 2.4 mg once weekly (IMPACT Phase 2b dose — no approved dose) · once weekly subcutaneous — investigational; Phase 3 planned 2026
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
Distilled themes from named communities — Reddit threads, forums, creator commentary. Not direct quotes; not clinical evidence. Useful for calibrating expectations against what real self-experimenters report.
Pemvidutide is essentially unknown outside the MASH/hepatology community. The 59.1% MASH resolution figure is striking for liver-disease patients who've seen mostly marginal interventions. The 6.2% weight loss relative to other GLP-1s is framed as a feature not a bug ('my doctor isn't using this for weight — it's for my liver'). AUD signal is generating separate interest in addiction-medicine circles.